Key result
Review details the utility of levosimendan among intravenous inotropic therapies for AHF.
Why the study?
Intravenous treatments in acute heart failure are administered heterogeneously with limited guideline adherence, and recent decades have seen a lack of successful innovation or positive long-term mortality data.
This review highlights the utility of levosimendan among intravenous inotropic and inodilating therapies for acute heart failure, a field that has seen limited successful innovation in recent decades.
No takes yet. Share an insight, caveat, or question.
Levosimendan may retain a role among AHF inotropes; leaves open the need for modern RCTs to clarify positioning and outcomes.
Guarracino et al. (2020) conducted a review in Acute heart failure (AHF). Levosimendan and other i.v. inotropic and inodilating therapies was evaluated. This review focuses on the utility of the calcium sensitizer and inodilator levosimendan within the wider context of intravenous inotropic and inodilating therapies for acute heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: